1. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
- Author
-
Collins GP, Rueda A, Salles G, von Tresckow B, and Zaja F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Brentuximab Vedotin, Child, Child, Preschool, Combined Modality Therapy, Female, France, Germany, Humans, Italy, Male, Middle Aged, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care statistics & numerical data, Retrospective Studies, Spain, Transplantation, Autologous, United Kingdom, Young Adult, Hodgkin Disease therapy, Immunoconjugates therapeutic use, Stem Cell Transplantation methods
- Abstract
We examined real-world data on management of relapsed/refractory Hodgkin lymphoma (R/R HL) in five European countries and the consistency of these data with guideline recommendations. Retrospective clinical and epidemiologic data for 509 patients with R/R HL treated between January 2014 and March 2015 were collected at centers in France, Germany, Italy, Spain, and the United Kingdom. Mean age was 46.3 years; 73.3% were receiving second-line therapy for a first relapse during the reporting period. Most patients received ABVD as front-line chemotherapy, except in Germany where escalated BEACOPP was used more often. The proportion of patients receiving stem cell transplantation (SCT) was 44%; 85% of transplants occurred at first relapse. Brentuximab vedotin (BV) was usually administered after autologous SCT, and was initiated for 65% of patients following SCT failure. Our findings suggest that R/R HL management across these countries is broadly consistent with guideline recommendations and that BV is well-integrated into treatment pathways.
- Published
- 2018
- Full Text
- View/download PDF